By working within this dose range (0.6–6 mg/kg, QD), we demonstrated the therapeutic benefit of PERK inhibition by delaying T1D onset in the NOD mouse model without observable negative impact on the pancreatic islet. This evidence concerns the gene EIF2AK3 and type 1 diabetes mellitus.